Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRCA-19 RCT: UC-MSCs in COVID-19 ARDS
NCT04865107Phase 2Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of umbilical cord-derived mesenchymal stromal cells in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by Ottawa Hospital Research Institute. Started Apr 2021; status: completed.
02
Drugs
umbilical cord-derived mesenchymal stromal cells
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04865107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04865107.